# 21 U.S.C. 360ee Grants and contracts for development of drugs for rare diseases and conditions

21 U.S.C. 360ee Grants and contracts for development of drugs for rare diseases and conditions, “Grants and contracts for development of drugs for rare diseases and conditions”, is a U.S. Code section of [Part B—Drugs for Rare Diseases or Conditions](https://ontology.bommaritollc.com/id/01a0f06c-cb98-7071-a43e-8d27fa14a067); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f06c-cd22-753d-b72f-bdb9875c6f44>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f06c-cb65-7672-8fda-c39517ff08c0) › [Chapter 9—Federal Food, Drug, and Cosmetic Act](https://ontology.bommaritollc.com/id/01a0f06c-cb91-72e0-858b-060e8c845f23) › [Subchapter V—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb96-7040-b454-c8f18e0e95cb) › [Part B—Drugs for Rare Diseases or Conditions](https://ontology.bommaritollc.com/id/01a0f06c-cb98-7071-a43e-8d27fa14a067)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 21 U.S.C. 360ee](https://ontology.bommaritollc.com/id/01a0f06c-cd23-739e-b271-872ee5d10a27)
- `eli:cites`:
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [21 U.S.C. 360bb Designation of drugs for rare diseases or conditions](https://ontology.bommaritollc.com/id/01a0f06c-cd1e-70fc-bda3-7fe5eb2d38cf)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partB-sec360ee](https://ontology.bommaritollc.com/id/01a0f06c-cd22-753d-b72f-bdb8be642534)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f06c-d15e-71bc-a1dd-7afedca55e74)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-2d7b-719e-83dc-377e36e95186)
  - [evidence from https://www.govinfo.gov/link/uscode/21/360ee?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f15-fe36-7510-b405-a22c852d5f06)
- `schema:isPartOf`: [Part B—Drugs for Rare Diseases or Conditions](https://ontology.bommaritollc.com/id/01a0f06c-cb98-7071-a43e-8d27fa14a067)
- `schema:legislationIdentifier`: 21 U.S.C. 360ee
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Grants and contracts for development of drugs for rare diseases and conditions
- `schema:url`: [https://www.govinfo.gov/link/uscode/21/360ee?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/21/360ee?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 U.S.C. 360ee Grants and contracts for development of drugs for rare diseases and conditions

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/21/360ee?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partB-sec360ee) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Amended by (12; `eli:amends`):
  - [Pub. L. 100-290](https://ontology.bommaritollc.com/id/01a0f06c-d330-73fb-854a-f0dcc4cca24d)
  - [Pub. L. 105-115](https://ontology.bommaritollc.com/id/01a0f06c-d29f-7443-a96a-3934363a8187)
  - [Pub. L. 107-281](https://ontology.bommaritollc.com/id/01a0f06c-d330-73fb-854a-f0eb680a8379)
  - [Pub. L. 110-85](https://ontology.bommaritollc.com/id/01a0f06c-d2ac-7439-ab06-bdf3d920772b)
  - [Pub. L. 112-144](https://ontology.bommaritollc.com/id/01a0f06a-a3b6-70e5-8204-79bb2755f506)
  - [Pub. L. 114-255](https://ontology.bommaritollc.com/id/01a0ee1d-96d5-7151-84b6-b5e19f0e00ec)
  - [Pub. L. 115-52](https://ontology.bommaritollc.com/id/01a0f06c-d2f5-7295-8628-c43a73a54615)
  - [Pub. L. 117-180](https://ontology.bommaritollc.com/id/01a0f06a-a3dc-779c-933c-4e4b12b48124)
  - [Pub. L. 117-229](https://ontology.bommaritollc.com/id/01a0ee1d-97fa-71e5-9133-25d78f05040d)
  - [Pub. L. 117-328](https://ontology.bommaritollc.com/id/01a0edf4-a3b3-73ad-8a5b-366dfc33cea1)
  - [Pub. L. 98-551](https://ontology.bommaritollc.com/id/01a0f06c-d32f-7664-b81d-e9af2d1a882f)
  - [Pub. L. 99-91](https://ontology.bommaritollc.com/id/01a0f06c-d32d-7698-b93c-3488d74aef5d)
- Cited by (7; `eli:cites`):
  - [21 CFR 101.9 Nutrition labeling of food.](https://ontology.bommaritollc.com/id/01a0f094-bd77-7209-9b47-748ce0627727)
  - [21 CFR 172.345 Folic acid (folacin).](https://ontology.bommaritollc.com/id/01a0f094-c09a-722e-baa3-84222bedc169)
  - [21 U.S.C. 321 Definitions; generally](https://ontology.bommaritollc.com/id/01a0f06c-cc8c-7030-ab68-1def0b197dcb)
  - [21 U.S.C. 343 Misbranded food](https://ontology.bommaritollc.com/id/01a0f06c-cca3-7182-b25e-3e24d5de5215)
  - [42 U.S.C. 1382a Income; earned and unearned income defined; exclusions from income](https://ontology.bommaritollc.com/id/01a0f07c-e091-7145-984c-1ed718309935)
  - [42 U.S.C. 236 Orphan Products Board](https://ontology.bommaritollc.com/id/01a0f07c-d8fc-7062-9749-1d5dcb64a256)
  - [7 CFR 246.2 Definitions.](https://ontology.bommaritollc.com/id/01a0ee02-269d-7216-bfa2-339b569bda37)
- Rules made under it (7; `eli:based_on`):
  - [21 CFR Part 201—Labeling](https://ontology.bommaritollc.com/id/01a0f094-b837-76de-94de-1fdabf2c1fc1)
  - [21 CFR Part 3—Product jurisdiction](https://ontology.bommaritollc.com/id/01a0f094-b7dc-7010-b821-be4791210aae)
  - [21 CFR Part 50—Protection of human subjects](https://ontology.bommaritollc.com/id/01a0f094-b7f0-7092-8cfc-6d60da0417f5)
  - [21 CFR Part 56—Institutional Review Boards](https://ontology.bommaritollc.com/id/01a0f094-b7f2-72a4-82d6-ac180848fce4)
  - [21 CFR Part 601—Licensing](https://ontology.bommaritollc.com/id/01a0f094-b882-764a-a051-b44410b6e848)
  - [21 CFR Part 740—Cosmetic product warning statements](https://ontology.bommaritollc.com/id/01a0f094-b88d-71bd-8d90-cd0e83729420)
  - [21 CFR Part 812—Investigational device exemptions](https://ontology.bommaritollc.com/id/01a0f094-b896-7341-a342-c3a0aea5ee4f)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 97-414](https://ontology.bommaritollc.com/id/01a0ee1d-951e-70e8-a68c-4a5cc7f187f7)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f06c-cd22-753d-b72f-bdb9875c6f44.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f06c-cd22-753d-b72f-bdb9875c6f44.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f06c-cd22-753d-b72f-bdb9875c6f44.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f06c-cd22-753d-b72f-bdb9875c6f44)
Cite as: 21 U.S.C. 360ee Grants and contracts for development of drugs for rare diseases and conditions. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f06c-cd22-753d-b72f-bdb9875c6f44
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
